Objective:

To analyze the knowledge structure and current research trends in immune checkpoint inhibitors induced colitis using bibliometric methods, including specific tools and metrics.

Key Findings:

• 1,010 papers on ICI-induced colitis were identified from 62 countries/regions.
• The United States led in publication volume (n=470 publications) and total citations (n=41,125 citations).
• The University of Texas MD Anderson Cancer Center had the highest number of publications (n=83).
• Wang Yinghong was the most prolific author (n=48 publications).
• The Journal for Immunotherapy of Cancer was the most published journal (n=60 papers).
• Key research trends included Ipilimumab, immunotherapy, Nivolumab, melanoma, cancer, and Pembrolizumab.

Interpretation:

The study highlights the significant growth and interest in ICI-induced colitis research, indicating a need for further exploration of combination therapies, clinical management strategies, and biomarkers, which could enhance patient outcomes.

Limitations:

• The analysis was limited to English-language articles and specific publication types (articles and reviews), which may exclude relevant studies in other languages.
• The study did not include patient or trial participant data, limiting the applicability of findings to clinical practice.

Conclusion:

Future research should focus on combination therapies, clinical management strategies, pathogenic mechanisms, fecal microbiota transplantation, and identifying predictive and diagnostic biomarkers for adverse events, emphasizing the importance of these areas in improving patient care.